Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 3, 1997, Pages 303-307

  Colleoni, M ^a,b   Graiff, C ^a   Nelli, P ^a   Vicario, G ^a   Sgarbossa, G ^a   Pancheri, F ^a   Manente, P ^a  

^a City Hospital   (Italy)

^b Cities   (Italy)

Author keywords

Brain metastases; Breast cancer; Lung cancer

Indexed keywords

CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; LOMUSTINE; NAVELBINE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST ADENOCARCINOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LOMUSTINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0030982221     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199706000-00020     Document Type: Article

References (33)

1. West Y, Moore M. Intracranial metastases: behavioral patterns related to primary site and results of treatment by whole brain irradiations. Int J Radiat Oncol Biol Phys 1980;6:11-5.
2. Posner JB. Management of central nervous system metastases. Semin Oncol 1977;4:81-91.
3. De Angelis LM. Management of brain metastases. Cancer Invest 1994;2:156-65.
4. Di Stefano A, Yap HY, Hortobagyi GN, et al. The natural history of breast cancer patients with brain metastases. Cancer 1979;44:1913-8.
5. Kamby C, Soerensen PS. Characteristics of patients with short and long survival after detection of intracranial metastases from breast cancer. J Neurol Oncol 1988;6:37-45.
6. Galicich JH, Sunderasan N, Thaler HT. Surgical treatment of single brain metastases: evaluation of results by computerized tomography scanning. J Neurosurg 1981;53:66-7.
7. Order SE, Hellman S, Von Essen CF, et al. Improvement in quality of survival following whole-brain irradiation for brain metastases. Radiology 1968;91:149-53.
8. Caincross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980;7:529-41.
9. Horton J, Baxter DH, Olson KB. The management of metastases of the brain by irradiation and corticosteroids. AJR 1971;3: 334-6.
10. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 1980;6: 1-8.
11. Gelber RD, Larson M, Borgelt BB, et al. Equivalence of radiation schedules for palliative treatment of brain metastases in patients with favorable prognosis. Cancer 1981;48:1749-53.
12. Santini A, Malacarne P, Indelli M, et al. Combination chemotherapy with carboplatin and etoposide of brain metastases from cancer. Eur J Cancer 1994;8:1205-6.
13. Chang DB, Yang PC, Luh KT, et al. Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment. Chest 1992;5:1293-7.
14. Robinet G, Richard P, Rouhart F, et al. Inoperable brain metastases from bronchogenic cancers. Value of combined chemotherapy with cisplatin and 5-fluorouracil. Rev Neurol 1992;148:493-5.
15. Ushio Y, Arita N, Hayakawa T, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 1991;2:201-5.
16. Rosner D, Nemoto T, Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58: 832-9.
17. Rosner D, Nemoto T, Pickren J, et al. Management of brain metastases from breast cancer by combination chemotherapy. J Neurooncol 1983;1:131-7.
18. Boogerd W, Dalesio O, Bais EM, et al. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;5:972-80.
19. Besenval M, Delgado M, Demarez JP, et al. Safety and tolerance of navelbine in phase I-II clinical studies. Semin Oncol 1989;16(suppl 4):37-40.
20. Cvitkovic E, Izzo J. The current and future place of vinorelbine in cancer therapy. Drug 1992;44(suppl 4):36-45.
21. Siegers HP. Chemotherapy for brain metastases: recent developments and clinical considerations. Cancer Treat Rev 1990;17:63-76.
22. Cocconi G, Lottici R, Bisagni, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;9:327-34.
23. Ushio Y, Posner JB, Shapiro WR. Chemotherapy of experimental meningeal carcinomatosis. Cancer Res 1977;37:1232-7.
24. Hasegawa H, Shapiro WS, Posner JB. Chemotherapy of experimental metastatic brain tumors in female nistar rats. Cancer Res 1979;39:2691-7.
25. Hildebrand J, Brihaye J, Wagenknecht L, et al. Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors. Eur J Cancer 1975;11: 585-7.
26. Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992;4:251-60.
27. Workman P. The pharmacology of brain tumor chemotherapy. In: Bleehen NM, ed. Tumors of the brain. Berlin: Springer-Verlag, 1985:183-200.
28. Twelves CJ, Souhami RL. Should cerebral metastases be treated by chemotherapy alone? Ann Oncol 1991;2:15-7.
29. Vick NA, Bigner DD. Microvascular abnormalities in virally induced canine brain tumors: structural bases for altered blood-brain barrier function. J Neurol Sci 1972;17:29-39.
30. Vick NA, Khandekar JD, Bigner DD. Chemotherapy of brain tumors: the blood-brain barrier is not a factor. Arch Neurol 1977;34:523-6.
31. Newwelt EA, Frenkel EP. Is there a therapeutic role for bloodbrain barrier disruption? Ann Intern Med 1980;93:137-9.
32. Bourke RS, West CR, Cheda G, et al. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973;33:1735-46.
33. Stewart DJ, Leavens M, Maor M, et al. Human central nervous system distribution of cis-diammine-dichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982;42:2474-9.